Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION:
5-HT(2A) receptor antagonists appear to assume an intermediate position by being marginally superior to placebo but inferior to conventional antipsychotic drugs. Three previous 5-HT(2A) receptor antagonists have been discontinued after Phase II or III trials, and available Phase IIa data on the remaining 5-HT(2A) receptor antagonist will need substantial additional validation to be approved as a new treatment strategy against schizophrenia.
|
Authors | Bjørn H Ebdrup, Hans Rasmussen, Jørn Arnt, Birte Glenthøj |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 20
Issue 9
Pg. 1211-23
(Sep 2011)
ISSN: 1744-7658 [Electronic] England |
PMID | 21740279
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antipsychotic Agents
- Fluorobenzenes
- Phenols
- Piperidines
- Receptor, Serotonin, 5-HT2A
- Serotonin 5-HT2 Receptor Antagonists
- SR 46349B
- Urea
- volinanserin
- pimavanserin
|
Topics |
- Antipsychotic Agents
(therapeutic use)
- Brain
(drug effects, metabolism)
- Fluorobenzenes
(therapeutic use)
- Humans
- Phenols
(therapeutic use)
- Piperidines
(therapeutic use)
- Positron-Emission Tomography
- Receptor, Serotonin, 5-HT2A
(drug effects)
- Schizophrenia
(drug therapy)
- Serotonin 5-HT2 Receptor Antagonists
(therapeutic use)
- Urea
(analogs & derivatives, therapeutic use)
|